In this study, ORR (63% vs. 36.7%–46%, respectively) and median PFS (10.6 vs. 5.5–9.3 months, respectively) were higher than those reported in a previous study of anti-PD-1 antibody combined with TKI for unresectable HCC (41). Here, PDCD1 is linked to hepatocellular carcinoma.